ArticleCancers2026
A TP53-Pathway-Based Prognostic Signature for Radiotherapy and Functional Validation of TP53I3 in Non-Small-Cell Lung Cancer.
Xiang Huang, Li Jiao, Xu Cheng, Yue Fang, Jian Qi, Zongtao Hu, Bo Hong, Jinfu Nie, Hongzhi Wang
Abstract read
In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Xiang HuangUniversity of Science and Technology of China, Hefei 230052, China.
Li JiaoHefei Cancer Hospital of CAS, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences (CAS), Hefei 230031, China.
Xu ChengHefei Cancer Hospital of CAS, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences (CAS), Hefei 230031, China.
Yue FangHefei Cancer Hospital of CAS, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences (CAS), Hefei 230031, China.ORCID 0000-0002-5863-6103 Jian QiHefei Cancer Hospital of CAS, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences (CAS), Hefei 230031, China.
Zongtao HuHefei Cancer Hospital of CAS, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences (CAS), Hefei 230031, China.
Jinfu NieHefei Cancer Hospital of CAS, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences (CAS), Hefei 230031, China.
Hongzhi WangUniversity of Science and Technology of China, Hefei 230052, China.
Funding
Collaborative Innovation Program of Hefei Science Center, CAS 2022HSC-CIP015National Natural Science Foundation of China 81872438Program of Clinical Medical Translational Research in Anhui Province 202304295107020092Program of Research and Development of Key Common Technologies and Engineering of Major Scientific and Technological Achievements in Hefei 2021YL007
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
nomogramsnon-small-cell lung cancerprognosisradiotherapyTP53I3TP53 signaling pathway
Identifiers
PMID41681932
PMCPMC12896867
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390